Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus Camrelizumab in Refractory Osteosarcoma
NCT03359018Phase 2Completed
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2018
- Primary completion
- Oct 2019
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in osteosarcoma (OS), sponsored by Peking University People's Hospital. Started Jan 2018; status: completed.
02
Drugs
camrelizumab
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT03359018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03359018.